These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38339133)

  • 21. Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.
    Chen H; Li XZ; Chen JQ; Ren TS; Zhang YS; Wang YN; Zhao QC
    Medicine (Baltimore); 2023 Jul; 102(27):e34122. PubMed ID: 37417602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
    Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA
    Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
    Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
    Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy.
    Dhanapalaratnam R; Issar T; Lee ATK; Poynten AM; Milner KL; Kwai NCG; Krishnan AV
    Diabetologia; 2024 Mar; 67(3):561-566. PubMed ID: 38189936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
    Herrou J; Mabilleau G; Lecerf JM; Thomas T; Biver E; Paccou J
    Calcif Tissue Int; 2024 Feb; 114(2):86-97. PubMed ID: 37999750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.
    von Arx LB; Rachman J; Webb J; Casey C; Patel A; Diomatari C; Wood R; Idris I
    Diabetes Obes Metab; 2023 May; 25(5):1331-1340. PubMed ID: 36692268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Consensus recommendations on utilizing glucagon-like peptide-1(GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus].
    ;
    Zhonghua Nei Ke Za Zhi; 2020 Nov; 59(11):836-846. PubMed ID: 33120487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
    Madsbad S; Holst JJ
    Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plaque-targeted, proteolysis-resistant, activatable and MRI-visible nano-GLP-1 receptor agonist targets smooth muscle cell differentiation in atherosclerosis.
    Maiseyeu A; Di L; Ravodina A; Barajas-Espinosa A; Sakamoto A; Chaplin A; Zhong J; Gao H; Mignery M; Narula N; Finn AV; Rajagopalan S
    Theranostics; 2022; 12(6):2741-2757. PubMed ID: 35401813
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study.
    Palanca A; Ampudia-Blasco FJ; Calderón JM; Sauri I; Martinez-Hervás S; Trillo JL; Redón J; Real JT
    Diabetes Res Clin Pract; 2024 Jan; 207():111071. PubMed ID: 38142748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network.
    García-Vega D; Sánchez-López D; Rodríguez-Carnero G; Villar-Taibo R; Viñuela JE; Lestegás-Soto A; Seoane-Blanco A; Moure-González M; Bravo SB; Fernández ÁL; González-Juanatey JR; Eiras S
    Cardiovasc Diabetol; 2024 Jan; 23(1):1. PubMed ID: 38172989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
    Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
    J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
    Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
    Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
    Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
    Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
    Nauck MA; Meier JJ
    Eur J Endocrinol; 2019 Dec; 181(6):R211-R234. PubMed ID: 31600725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group.
    Janez A; Muzurovic E; Stoian AP; Haluzik M; Guja C; Czupryniak L; Duvnjak L; Lalic N; Tankova T; Bogdanski P; Papanas N; Nunes JS; Kempler P; Fras Z; Rizzo M
    Int J Cardiol; 2022 Oct; 365():8-18. PubMed ID: 35905827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.
    Giugliano D; Scappaticcio L; Longo M; Caruso P; Maiorino MI; Bellastella G; Ceriello A; Chiodini P; Esposito K
    Cardiovasc Diabetol; 2021 Sep; 20(1):189. PubMed ID: 34526024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.